These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19394232)

  • 21. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
    Feng WF; Zhao YB; Huang W; Yang YZ
    J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as potent non-peptidic inhibitors of caspase-3.
    Havran LM; Chong DC; Childers WE; Dollings PJ; Dietrich A; Harrison BL; Marathias V; Tawa G; Aulabaugh A; Cowling R; Kapoor B; Xu W; Mosyak L; Moy F; Hum WT; Wood A; Robichaud AJ
    Bioorg Med Chem; 2009 Nov; 17(22):7755-68. PubMed ID: 19836248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
    Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, molecular modelling and enzymatic evaluation of (+/-)3,5-diphenyl-2-thioxoimidazolidin-4-ones as new potential cyclooxygenase inhibitors.
    Gauthier MP; Michaux C; Rolin S; Vastersaegher C; de Leval X; Julémont F; Pochet L; Masereel B
    Bioorg Med Chem; 2006 Feb; 14(4):918-27. PubMed ID: 16214349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold.
    Maingot L; Leroux F; Landry V; Dumont J; Nagase H; Villoutreix B; Sperandio O; Deprez-Poulain R; Deprez B
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6213-6. PubMed ID: 20846863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
    Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2741-4. PubMed ID: 12873505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of human neutrophil elastase based on a highly functionalized N-amino-4-imidazolidinone scaffold.
    He G; Dou D; Wei L; Alliston KR; Groutas WC
    Eur J Med Chem; 2010 Sep; 45(9):4280-7. PubMed ID: 20638756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
    Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore modeling for the identification of small-molecule inhibitors of TACE.
    Liu LJ; Leung KH; Lin S; Chan DS; Susanti D; Rao W; Chan PW; Ma DL; Leung CH
    Methods; 2015 Jan; 71():92-7. PubMed ID: 25260600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
    J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
    Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
    SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of potent and selective TACE inhibitors via the S1 pocket.
    Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
    Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.
    Shiozaki M; Imai H; Maeda K; Miura T; Yasue K; Suma A; Yokota M; Ogoshi Y; Haas J; Fryer AM; Laird ER; Littmann NM; Andrews SW; Josey JA; Mimura T; Shinozaki Y; Yoshiuchi H; Inaba T
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6213-7. PubMed ID: 19767207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.
    Girijavallabhan VM; Chen L; Dai C; Feltz RJ; Firmansjah L; Li D; Kim SH; Kozlowski JA; Lavey BJ; Kosinski A; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Tong L; Wong MK; Yang DY; Yang L; Yu W; Zhou G; Guo Z; Orth P; Madison V; Bian H; Lundell D; Niu X; Shah H; Sun J; Umland S
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7283-7. PubMed ID: 21106451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
    Liu S; Liu S; Wang Y; Liao Z
    Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
    Guo Z; Orth P; Wong SC; Lavey BJ; Shih NY; Niu X; Lundell DJ; Madison V; Kozlowski JA
    Bioorg Med Chem Lett; 2009 Jan; 19(1):54-7. PubMed ID: 19054672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.
    Moriyama H; Tsukida T; Inoue Y; Yokota K; Yoshino K; Kondo H; Miura N; Nishimura S
    J Med Chem; 2004 Apr; 47(8):1930-8. PubMed ID: 15055993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
    Murumkar PR; Zambre VP; Yadav MR
    J Comput Aided Mol Des; 2010 Feb; 24(2):143-56. PubMed ID: 20179991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.